199 related articles for article (PubMed ID: 11456286)
1. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
2. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
3. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
4. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
7. Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man.
Ligtenberg JJ; Venker CE; Sluiter WJ; Reitsma WD; Van Haeften TW
Eur J Clin Invest; 1997 Aug; 27(8):685-9. PubMed ID: 9279533
[TBL] [Abstract][Full Text] [Related]
8. Influence of gliclazide on glucose-stimulated insulin release in man.
van Haeften TW; Veneman TF; Gerich JE; van der Veen EA
Metabolism; 1991 Jul; 40(7):751-5. PubMed ID: 1870430
[TBL] [Abstract][Full Text] [Related]
9. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
[TBL] [Abstract][Full Text] [Related]
11. [Insulin resistance and insulin secretion in type II non-obese diabetics].
Pelikánová T; Válek J; Kazdová L; Saudek F; Karasová L
Cas Lek Cesk; 1994 Mar; 133(6):172-6. PubMed ID: 8156572
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
[TBL] [Abstract][Full Text] [Related]
13. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
14. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
[TBL] [Abstract][Full Text] [Related]
15. First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal test.
Rave K; Sidharta PN; Dingemanse J; Heinemann L; Roggen K
Diabetes Technol Ther; 2010 Feb; 12(2):117-23. PubMed ID: 20105041
[TBL] [Abstract][Full Text] [Related]
16. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Portha B; Serradas P
Am J Med; 1991 Jun; 90(6A):15S-21S. PubMed ID: 1831320
[TBL] [Abstract][Full Text] [Related]
17. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Chazan AC; Gomes MB
Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
An Z; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
[TBL] [Abstract][Full Text] [Related]
19. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
[TBL] [Abstract][Full Text] [Related]
20. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.
Korytkowski M; Thomas A; Reid L; Tedesco MB; Gooding WE; Gerich J
Diabetes Care; 2002 Sep; 25(9):1607-11. PubMed ID: 12196435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
